Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Church & Dwight Co., Inc. (CHD) vs Novo Nordisk A/S (NVO) Price & Performance

Church & Dwight Co., Inc.Trade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Church & Dwight Co., Inc. vs Novo Nordisk A/S — how do they compare? Church & Dwight Co., Inc. trades at $101.2 (market cap $24.38B), while Novo Nordisk A/S trades at $46.03 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 8.5× Church & Dwight Co., Inc.'s market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.

CHDNVO
Market Cap
$24.38B$207.85B
Sector
Consumer StaplesHealth
52-Week High
$105.26$63.98
52-Week Low
$81.60$35.29
Enterprise Value
$26.38B$222.55B
Dividend Yield
1.2%3.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Church & Dwight Co., Inc.

Church & Dwight (CHD) trades at $103.30, up 0.06% today, near its consensus price target of $103.57. The stock shows bullish technical signals with strong moving averages, though oscillators indicate overbought conditions. Fundamentally, Q2 2026 earnings met estimates with 5.8% organic sales growth, and the company raised full-year guidance. Recent news highlights volume-driven performance and market share gains.

The outlook remains positive given raised earnings guidance and consistent dividend payments, but risks include high valuation multiples and competitive pressures. Analyst consensus is bullish with 53% buy ratings, supporting a stable investment case for long-term growth in the consumer staples sector.

Novo Nordisk A/S

NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.

The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Church & Dwight Co., Inc.

Church & Dwight is the leading producer of baking soda in the world. Beyond baking soda, the products in its portfolio have vast category reach, including laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its mix also includes Xtra, Trojan, OxiClean, First Response, Nair, L'il Critters/Vitafusion, Orajel, and WaterPik, which together with Arm & Hammer constitute more than 80% of its annual sales and profits. In early 2019, the firm announced the addition of Flawless, which manufactures electric shaving products for women. At the end of 2020, the firm acquired Zicam, a leading brand in the cough/cold-shortening category. Church & Dwight derives more than 80% of its sales from its home market in the U.S.

Read more on CHD

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO